This site is intended for healthcare professionals
Light microscopy of the internal lining of the urinary bladder; haematoxylin and eosin stain
Managing High-Risk NMIBC

Diagnosis: Which tools should be used when?

Last updated: 13th Oct 2025
Published: 13th Aug 2025

After listening to this podcast, are you more confident in selecting appropriate diagnostic tools and avoiding common pitfalls when assessing patients with NMIBC?

Episode 1. “Selecting the right guideline for the right patient is the art of bladder cancer management,” says Ashish Kamat. But what does that look like in practice – especially when diagnostic tools, cystoscopy techniques, and biomarker use vary across regions? In this episode, Kamat and Morgan Rouprêt explore how NMIBC diagnosis and staging unfold in real-world clinical settings. View transcript.

Chapters
00:00 Welcome and introductions
00:32 Choosing the right diagnostic tools
02:47 Cystoscopy techniques and tips
05:10 Cytology and biomarkers in NMIBC
08:24 Imaging as an adjunct for staging
11:46 Regional practice vs clinical guidelines
15:24 Summary and wrap-up

 

Next episode

Return to episode list


Meet the guest speaker

Morgan Roupret, circle profile pictureMorgan Rouprêt, MD, PhD

Morgan Rouprêt is a Professor of Urology at AP-HP Sorbonne University and Pitié-Salpêtrière Hospital, Paris, France. He serves as Chair of the European Section of Onco-Urology (ESOU) and is Editor-in-Chief of European Urology Oncology.

Disclosures: Consulting and speaker engagements with Astellas, AstraZeneca, CG Oncology, Ferring, Intuitive Surgical, Janssen, MSD, Pfizer, and Roche.

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information 

 

By providing your email address, you are opting in to receive our monthly newsletter.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.